LIU De-chun, ZHAO Yun-xia, WU Li-gao, CHENG Ze-nong, FENG Zhen-zhong. Expression of α-methylacyl-CoA-racemase in breast cancer and its significance[J]. Journal of Bengbu Medical University, 2009, 34(4): 284-286.
Citation:
LIU De-chun, ZHAO Yun-xia, WU Li-gao, CHENG Ze-nong, FENG Zhen-zhong. Expression of α-methylacyl-CoA-racemase in breast cancer and its significance[J]. Journal of Bengbu Medical University, 2009, 34(4): 284-286.
LIU De-chun, ZHAO Yun-xia, WU Li-gao, CHENG Ze-nong, FENG Zhen-zhong. Expression of α-methylacyl-CoA-racemase in breast cancer and its significance[J]. Journal of Bengbu Medical University, 2009, 34(4): 284-286.
Citation:
LIU De-chun, ZHAO Yun-xia, WU Li-gao, CHENG Ze-nong, FENG Zhen-zhong. Expression of α-methylacyl-CoA-racemase in breast cancer and its significance[J]. Journal of Bengbu Medical University, 2009, 34(4): 284-286.
Objective: To investigate the expression of alpha-methylacyl-CoA-racemase(AMACR) in breast cancer and its clinico-pathological significance.Methods: AMACR and ER,PR,C-erbB-2 were detected in 73 cases of breast cancer and 36 cases of benign mammary lesions using immunohistochemical technique(S-P method),and the results were studied microscopically and statistically.Results: The positive rates of AMACR were 86.3% in breast cancer and 55.6% in benign mammary lesions,which had statistical significance(P<0.01).The expression of AMACR in breast cancer showed no difference among the typing,grading,and ER,PR,C-erbB-2 immunoplenotypes(P>0.05).Conclusions: AMACR is not only the biomarker of prostate cancer but can also be used in the pathological diagnosis of breast cancer.
DownLoad: